Climb Bio Valuation
| CLYM Stock | 7.07 0.08 1.12% |
At this time, the firm appears to be undervalued. Climb Bio shows a prevailing Real Value of USD8.72 per share. The current price of the firm is USD7.07. Our model approximates the value of Climb Bio from analyzing the firm fundamentals such as Return On Equity of -0.26, shares owned by insiders of 0.79 %, and Current Valuation of 401.2 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Climb Bio's price fluctuation is relatively risky at this time. Calculation of the real value of Climb Bio is based on 3 months time horizon. Increasing Climb Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Climb stock is determined by what a typical buyer is willing to pay for full or partial control of Climb Bio. Since Climb Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Climb Stock. However, Climb Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.07 | Real 8.72 | Hype 7.88 | Naive 7.61 |
The intrinsic value of Climb Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Climb Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Climb Bio helps investors to forecast how Climb stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Climb Bio more accurately as focusing exclusively on Climb Bio's fundamentals will not take into account other important factors: About Climb Bio Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Climb Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Climb Bio based exclusively on its fundamental and basic technical indicators. By analyzing Climb Bio's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Climb Bio's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Climb Bio. We calculate exposure to Climb Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Climb Bio's related companies. When determining whether Climb Bio is a strong investment it is important to analyze Climb Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Climb Bio's future performance. For an informed investment choice regarding Climb Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Will Biotechnology sector continue expanding? Could Climb diversify its offerings? Factors like these will boost the valuation of Climb Bio. Projected growth potential of Climb fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Climb Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Climb Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Climb Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Climb Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.